1/15
05:21 pm
alxo
ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference [Yahoo! Finance]
Low
Report
ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference [Yahoo! Finance]
1/12
01:16 pm
alxo
ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks [Yahoo! Finance]
Neutral
Report
ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks [Yahoo! Finance]
1/8
11:00 am
alxo
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/8
08:30 am
alxo
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
Medium
Report
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
12/22
01:07 am
alxo
12/14
01:27 am
alxo
Medium
Report
12/7
08:00 am
alxo
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
Low
Report
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
12/6
01:36 am
alxo
11/18
11:14 am
alxo
ALX Oncology to Present at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
ALX Oncology to Present at Upcoming Investor Conferences [Yahoo! Finance]
11/18
11:00 am
alxo
ALX Oncology to Present at Upcoming Investor Conferences
Medium
Report
ALX Oncology to Present at Upcoming Investor Conferences
11/13
09:53 am
alxo
ALX Oncology (NASDAQ:ALXO) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $4.00 price target on the stock.
Low
Report
ALX Oncology (NASDAQ:ALXO) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $4.00 price target on the stock.
11/8
07:05 pm
alxo
ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ... [Yahoo! Finance]
Low
Report
ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ... [Yahoo! Finance]
11/7
08:15 am
alxo
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
High
Report
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/30
08:30 am
alxo
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
Medium
Report
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
10/23
12:30 pm
alxo
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
Low
Report
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference